Prescription Opioid Addiction Treatment Study (POATS)

Mass General Brigham

Status and phase: Completed; Phase 3

Conditions: Substance-related Disorders; Opiate Dependence; Opioid-related Disorders

Treatments: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse; Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse

Study type: Interventional

Funder types: Other

Identifiers

NCT00316277

NIDA-CTN-0030

Details and patient eligibility

About

The purpose of this study is to determine whether treatment outcome for subjects dependent on prescription opioid analgesics can be improved by adding individual drug counseling to the prescription of buprenorphine/naloxone with standard medical management. This will be examined during: a) an initial four-week treatment with taper; b) a 12-week stabilization treatment for those who do not respond successfully to the initial treatment; and c) a long-term follow-up assessment at 1.5 years, 2.5 years, and 3.5 years after treatment.

Full description

This is a randomized 2-phase, open-label; multi-center study conducted in outpatient treatment settings. The main objective of this study is to identify an effective sublingual buprenorphine/naloxone treatment regimen for subjects dependent on prescription opioids. Phase 1 of this study will assess the prevailing one-month detoxification practice. This phase will assess the benefits of individual drug counseling in a short-term treatment paradigm. The second phase of this study will assess the benefit of individual drug counseling in a longer-term treatment paradigm for participants who did not respond successfully to the short-term buprenorphine/naloxone treatment. There is also a long-term follow-up assessment to determine outcomes at 1.5 years, 2.5 years, and 3.5 years after treatment.

Enrollment: 653 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years old or older
• Physically dependent on opioids
• Meet DSM-IV criteria for opioid dependence

Exclusion criteria

• Known allergy or sensitivity to buprenorphine or naloxone
• Unstable psychiatric disorder
• Pregnant or lactating females
• Liver function test results greater than 5 times the upper limit of normal range

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

653 participants in 2 patient groups

Buprenorphine/Nx with EMM

Experimental group

Treatment:

Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse

Buprenorphine/Nx with SMM

Active Comparator group

Treatment:

Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse